INVA

Innoviva, Inc.

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.

Innoviva, Inc. (INVA) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B (3.3) C- (2.0) B+ (3.8) C+ (2.7) C+ (2.6) B- (2.9)
2026-11-05 B (3.4) C (2.4) B+ (3.8) B- (2.9) C+ (2.7) B- (3.0)
2026-10-29 B (3.3) C (2.4) B+ (3.8) C+ (2.7) C+ (2.7) B- (3.0)
2026-10-22 B (3.3) C (2.4) B+ (3.8) C+ (2.6) C+ (2.6) B- (2.9)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe